Cited by 1,275Liver Disease Diagnosis and TreatmentUltrasound Imaging and ElastographyUltrasound in Clinical Applications

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Open access

Karlas, Thomas, Petroff, David, Sasso, Magali, Fan, Jian-Gao, Mi, Yu-Qiang, de Lédinghen, Victor, Kumar, Manoj, Lupsor-Platon, Monica, Han, Kwang-Hyub, Cardoso, Ana C., Ferraioli, Giovanna, Chan, Wah-Kheong, Wong, Vincent Wai-Sun, Myers, Robert P., Chayama, Kazuaki, Friedrich-Rust, Mireen, Beaugrand, Michel, Shen, Feng, Hiriart, Jean-Baptiste, Sarin, Shiv K., Badea, Radu, Jung, Kyu Sik, Marcellin, Patrick, Filice, Carlo, Mahadeva, Sanjiv, Wong, Grace Lai-Hung, Crotty, Pam, Masaki, Keiichi, Bojunga, Joerg, Bedossa, Pierre, Keim, Volker, Wiegand, Johannes·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2016.12.022

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of fatty liver underscores the need for non-invasive characterization of steatosis, such as the ultrasound based controlled attenuation parameter (CAP). Despite good diagnostic accuracy, clinical use of CAP is limited due to uncertainty regarding optimal cut-offs and the influence of covariates. We therefore conducted an individual patient data meta-analysis.Methods A review of the literature identified studies containing histology verified CAP data (M probe, vibration controlled transient elastography with FibroScan®) for grading of steatosis (S0-S3). Receiver operating characteristic analysis after correcting for center effects was used as well as mixed models to test the impact of covariates on CAP. The primary outcome was establishing CAP cut-offs for distinguishing steatosis grades.Results Data from 19/21 eligible papers were provided, comprising 3830/3968 (97%) of patients. Considering data overlap and exclusion criteria, 2735 patients were included in the final analysis (37% hepatitis B, 36% hepatitis C, 20% NAFLD/NASH, 7% other). Steatosis distribution was 51%/27%/16%/6% for S0/S1/S2/S3. CAP values in dB/m (95% CI) were influenced by several covariates with an estimated shift of 10 (4.5-17) for NAFLD/NASH patients, 10 (3.5-16) for diabetics and 4.4 (3.8-5.0) per BMI unit. Areas under the curves were 0.823 (0.809-0.837) and 0.865 (0.850-0.880) respectively. Optimal cut-offs were 248 (237-261) and 268 (257-284) for those above S0 and S1 respectively.Conclusions CAP provides a standardized non-invasive measure of hepatic steatosis. Prevalence, etiology, diabetes, and BMI deserve consideration when interpreting CAP. Longitudinal data are needed to demonstrate how CAP relates to clinical outcomes.Lay summary There is an increase in fatty liver for patients with chronic liver disease, linked to the epidemic of the obesity. Invasive liver biopsies are considered the best means of diagnosing fatty liver. The ultrasound based controlled attenuation parameter (CAP) can be used instead, but factors such as the underlying disease, BMI and diabetes must be taken into account. Registration: Prospero CRD42015027238.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.12.022

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statisctics and computing/Statistics and computing · doi:10.1007/978-0-387-21706-2 · Cited by 25,941
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Fitting Linear Mixed-Effects Models Using lme4Preprint
Bates, D. M., Maechler, M., Bolker, B. M., & Walker, S. (2014) · arXiv (Cornell University) · doi:10.3929/ethz-b-000105397 · Cited by 9,435
Histological grading and staging of chronic hepatitis.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., Groote, J. D., Gudat, F., Denk, H., Desmet, V., Korb, G., Macsween, R. N., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,290
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,189
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2015) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,002

Flagged first, then by citations

Show all 65 references

1 of the 65 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–300 of 1,000

Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD: findings from NHANES (2017–2020)
Xi, W., & Yang, A. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02027-x · Cited by 34
Characterizing Fatty Liver in vivo in Rabbits, Using Quantitative Ultrasound
Nguyen, T., Podkowa, A. S., Tam, A. Y., Arnold, E. C., Miller, R. J., Park, T. H., Do, M. N., & Oelze, M. L. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.03.021 · Cited by 36
Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease
Unger, L. W., Forstner, B., Schneglberger, S., Muckenhuber, M., Eigenbauer, E., Scheiner, B., Mandorfer, M., Trauner, M. A., & Reiberger, T. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01544-5 · Cited by 34
Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
Yen, H., Su, P., Huang, S., Wu, L., Hsu, T., Zeng, Y.-H., & Chen, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252286 · Cited by 34
Quality criteria for the measurement of liver stiffness
Boursier, J., Decraecker, M., Bourlière, M., Bureau, C., Ganne‐Carrié, N., & de Lédinghen, V. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101761 · Cited by 33
Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study
Lindfors, A., Strandberg, R., & Hagström, H. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00313-3 · Cited by 33
Liver disease in adults with α1‐antitrypsin deficiency
Mandorfer, M., Bucsics, T., Hutya, V., Schmid-Scherzer, K., Schaefer, B., Zoller, H., Ferlitsch, A., Peck‐Radosavljevic, M., Trauner, M. A., Ferenci, P., et al. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618764057 · Cited by 33
Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography
Kwon, E. Y., Kim, Y. R., Kang, D. M., Yoon, K., & Lee, Y. H. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.01.034 · Cited by 33
Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease
Chen, B. R., & Pan, C. Q. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101755 · Cited by 33
Liver involvement in patients with erythropoietic protoporphyria
Wensink, D., Coenen, S., Wilson, J. H. P., Wagenmakers, M. A. E. M., & Langendonk, J. G. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.007 · Cited by 33
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
Riebensahm, C., Berzigotti, A., Surial, B., Günthard, H. F., TARR, P. E., Furrer, H., Rauch, A., Wandeler, G., & Study, S. H. C. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac538 · Cited by 33
Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
Chen, J., Mao, X., Deng, M., & Luo, G. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002497 · Cited by 36
Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B
Wong, S., Chan, W., & Mohamed, R. B. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13361 · Cited by 32
Self-citation
Ultrasound Stratification of Hepatic Steatosis Using Hepatorenal Index
Johnson, S. I., Fort, D. G., Shortt, K. J., Therapondos, G., Galliano, G. E., Nguyen, T. H.-A., & Bluth, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11081443 · Cited by 32
Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease
Kuroda, H., Abe, T., Fujiwara, Y., Nagasawa, T., & Takikawa, Y. (2021) · Journal of Medical Ultrasonics · doi:10.1007/s10396-021-01123-0 · Cited by 32
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery
Tavaglione, F., Vincentis, A. D., Bruni, V., Gallo, I. F., Carotti, S., Tuccinardi, D., Spagnolo, G., Ciociola, E., Mancina, R. M., Jamialahmadi, O., et al. (2021) · Liver International · doi:10.1111/liv.15127 · Cited by 32
UEG Week 2018 Poster Presentations
Pittet, V., Aslan, N., Fournier, N., Decollogny, A., Schoepfer, A., Seibold, F., & Rodondi, P. Y. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618792819 · Cited by 32
Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial
El-Kady, R. R., Ali, A. K., Wakeel, L. M. E., Sabri, N. A., & Shawki, M. A. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221077958 · Cited by 32
Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome
Hsu, C. L., Lang, S., Demir, M., Fouts, D. E., Stärkel, P., & Schnabl, B. (2023) · Hepatology · doi:10.1097/hep.0000000000000238 · Cited by 31
Influence of Gender and Reproductive Factors on Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Xiong, M., Li, J., Yang, S., Zeng, F., Ji, Y., Liu, J., Wu, Q., He, Q., Jiang, R., Zhou, F., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000085 · Cited by 31
Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease
Lee, Y., Yoo, Y. J., Jung, Y. K., Kim, J. H., Seo, Y. S., Yim, H. J., Kim, I. H., Lee, S. Y., Kim, B., Kim, J. W., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000157 · Cited by 31
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Lee, D. H. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.243 · Cited by 32
Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort
Beyer, C., Hutton, C., Andersson, A., Imajo, K., Nakajima, A., Kiker, D., Banerjee, R., & Dennis, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249491 · Cited by 31
Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
Dietrich, C. F., Shi, L., Löwe, A., Dong, Y., Potthoff, A., Sparchez, Z. A., Teufel, A., Guth, S., Koch, J., Barr, R. G., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1491-1771 · Cited by 31
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
Calleja, J. L., Rivera‐Esteban, J., Aller, R., Hernández‐Conde, M., Abad, J., Pericàs, J. M., Benito, H. G., Serra, M. Á., Escudero, A., Ampuero, J., et al. (2022) · Liver International · doi:10.1111/liv.15323 · Cited by 31
Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology
Peng, D., Yu, Z., Wang, M., Shi, J., Sun, L., Zhang, Y., Zhao, W., Chen, C., Tang, J., Wang, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935390 · Cited by 31
A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis
Younossi, Z. M., Alkhouri, N., Cusi, K., Isaacs, S. D., Kanwal, F., Noureddin, M., Loomba, R. S., Ravendhran, N., Lam, B. P., Nader, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17346 · Cited by 31
Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Burgio, M. D., Castéra, L., Oufighou, M., Rautou, P., Paradis, V., Bédossa, P., Sartoris, R., Ronot, M., Bodard, S., Garteiser, P., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.034 · Cited by 31
Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients
Zhang, W., Li, Y., Li, S., Zhou, J., Wang, K., Li, Z., Chen, N., & Chen, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1278505 · Cited by 30
Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease
Khoo, S., Wong, V. W., Goh, G. B., Fan, J., Chan, W., Seto, W., & Chow, W. C. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14794 · Cited by 30
Self-citation
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Lee, J. S., Sinn, D. H., Park, S. Y., Shin, H. J., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Oh, J. H., et al. (2021) · Cancers · doi:10.3390/cancers13184567 · Cited by 30
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries
Graupera, I., Thiele, M. S., Ma, A. T., Serra‐Burriel, M., Pich, J., Fabrellas, N., Caballería, L., de Knegt, R. J., Grgurević, I., Reichert, M., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-13724-6 · Cited by 30
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study
Nguyen, V. H., Le, I., Ha, A. Y., Le, R. H., Rouillard, N. A., Fong, A. H., Gudapati, S. T., Park, J. E., Maeda, M., Barnett, S. D., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0205 · Cited by 30
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease
Lee, H. W., Kim, B. K., Kim, S. U., Park, J. Y., Kim, D. Y., Ahn, S. H., Kim, K. J., & Han, K. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4592-0 · Cited by 30
Self-citation
Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter
Park, H. E., Lee, H., Choi, S., Kwak, M., Yang, J. I., Yim, J. Y., & Chung, G. E. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1516-5 · Cited by 30
Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017–2018
Chen, Y., Lü, C., Ju, H., Zhou, Q., & Zhao, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405828 · Cited by 29
Identification of pediatric MASLD using insulin resistance indices
Song, K., Lee, E., Lee, H. S., Youn, Y. H., Baik, S. J., Shin, H. J., Chae, H. W., Lee, J., & Kwon, Y. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101419 · Cited by 32
Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial
Naimi, R. M., Hvistendahl, M., Nerup, N. A., Ambrus, R., Achiam, M. P., Svendsen, L. B., Grønbæk, H., Møller, H. J., Vilstrup, H., Steensberg, A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.016 · Cited by 29
Advances in ultrasound elastography for nonalcoholic fatty liver disease
Yoneda, M., Honda, Y., Nogami, A., Imajo, K., & Nakajima, A. (2020) · Journal of Medical Ultrasonics · doi:10.1007/s10396-020-01040-8 · Cited by 29
Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
Blank, V., Petroff, D., Beer, S., Böhlig, A., Heni, M., Berg, T., Bausback, Y., Dietrich, A., Tönjes, A., Hollenbach, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75227-x · Cited by 29
Self-citation
Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
Choi, S. J., Kim, S. M., Kim, Y. S., Kwon, O. S., Shin, S. K., Kim, K. K., Lee, K., Park, I. B., Choi, C. S., Chung, D. H., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0137 · Cited by 29
Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B
Hsueh, R.-C., Wu, W.-J., Lin, C.-L., Liu, C.-J., Huang, Y.-W., Hu, J.-T., Wu, C.-F., Sung, F.-Y., Liu, W.-J., & Yu, M.-W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s355540 · Cited by 29
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents
Ciardullo, S., Carbone, M., Invernizzi, P., & Perseghin, G. (2022) · Hepatology Communications · doi:10.1002/hep4.1969 · Cited by 29
The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population
Sookoian, S. C., & Pirola, C. J. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00893-6 · Cited by 29
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Seo, J. Y., Cho, E. J., Kim, M. J., Kwak, M., Yang, J. I., Chung, S. J., Yim, J. Y., Yoon, J. W., & Chung, G. E. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13099 · Cited by 29
Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD
De, A., Mehta, M., Singh, P., Bhagat, N., Mitra, S., Das, A., & Duseja, A. K. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01346-w · Cited by 29
Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis
Kuroda, H., Oguri, T., Kamiyama, N., Toyoda, H., Yasuda, S., Imajo, K., Suzuki, Y., Sugimoto, K., Akita, T., Tanaka, J., et al. (2023) · Radiology · doi:10.1148/radiol.230341 · Cited by 28
Association between body roundness index and risk of ultrasound-defined non-alcoholic fatty liver disease
Zhao, E., Wen, X., Qiu, W., & Zhang, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23429 · Cited by 28
Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study
He, Y., Yao, N., Tian, F., Liu, L., Lin, X., Chen, X., Duan, H., Jiang, Y., Yu, G., Song, C., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102973 · Cited by 31
Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation
Hobeika, C., Ronot, M., Guiu, B., Ferraioli, G., Iijima, H., Tada, T., Lee, D. H., Kuroda, H., Lee, Y. H., Lee, J. M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000895 · Cited by 28
Self-citation
US Markers and Necroinflammation, Steatosis, and Fibrosis in Metabolic Dysfunction–associated Steatotic Liver Disease: The iLEAD Study
Sugimoto, K., Moriyasu, F., Burgio, M. D., Vilgrain, V., Jesper, D., Strobel, D. D., Blank, V., Karlas, T., Grant, E. G., Kelahan, L. C., et al. (2024) · Radiology · doi:10.1148/radiol.233377 · Cited by 28
Self-citation
Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease
Grąt, K., Grąt, M., & Rowiński, O. (2020) · Biomedicines · doi:10.3390/biomedicines8090298 · Cited by 28
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients
Padole, P., Arora, A., Sharma, P., Chand, P., Verma, N., & Kumar, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.015 · Cited by 29
Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis
Jang, J. K., Kim, S. Y., Yoo, I. W., Cho, Y. B., Kang, H. J., & Lee, D. H. (2021) · European Radiology · doi:10.1007/s00330-021-08269-y · Cited by 28
Reproducibility of ultrasound-guided attenuation parameter (UGAP) to the noninvasive evaluation of hepatic steatosis
Zhao, Y., Jia, M., Zhang, C., Feng, X., Chen, J., Li, Q., Zhang, Y., Xu, W., Dong, Y., Jiang, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06879-0 · Cited by 28
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018
Truong, E., Yeo, Y. H., Cook‐Wiens, G., Muthiah, M. D., Yang, J. D., Sundaram, V., Chang, D. Y., Todo, T., Kim, I. K., Lu, S. C.-L., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1981 · Cited by 28
Self-citation
Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China
Li, D., Zhang, M., Wu, S., Tan, H., & Li, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-17511-6 · Cited by 29
Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population‐based study
Kardashian, A. A., Dodge, J. L., & Terrault, N. A. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17219 · Cited by 28
Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre
Nguyen, V., Li, J., Gan, J., Cordero, P., Ray, S., Solis-Cuevas, A., Khatib, M., & Oben, J. A. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/4697194 · Cited by 28
Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial
Liu, Q., Li, X., Pan, Y., Liu, Q., Li, Y., He, C., Zheng, N., Wang, Y., Wang, H., Wang, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155398 · Cited by 30
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 27
Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter
Yen, Y., Kuo, F. Y., Lin, C., Chen, C.-L., Chang, K., Tsai, M., & Hu, T. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.06.039 · Cited by 27
Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease
Lee, S. J., & Kim, S. U. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1608820 · Cited by 26
Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease
Ting, Y., Wong, S., Zaini, A. A., Mohamed, R. B., & Jalaludin, M. Y. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00491 · Cited by 27
Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil
Barros, B. S. V., Monteiro, F. C., Terra, C., & Gomes, M. B. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00649-0 · Cited by 27
Ultrasound-Based Quantification of Fibrosis and Steatosis with a New Software Considering Transient Elastography as Reference in Patients with Chronic Liver Diseases
Popa, A., Șirli, R., Popescu, A., Bâldea, V., Lupușoru, R., Bende, F., Cotrău, R., & Sporea, I. (2021) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2021.02.029 · Cited by 27
The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018
Bae, J. C., Beste, L. A., & Utzschneider, K. M. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1434 · Cited by 27
Development and validation of a new nomogram to screen for MAFLD
Zou, H., Zhao, F., Lv, X., Ma, X., & Xie, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01748-1 · Cited by 27
Circulating Extracellular Vesicle-Derived microRNAs as Novel Diagnostic and Prognostic Biomarkers for Non-Viral-Related Hepatocellular Carcinoma
Boonkaew, B., Satthawiwat, N., Pinjaroen, N., Chuaypen, N., & Tangkijvanich, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216043 · Cited by 27
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study
Nixdorf, L., Hartl, L., Ströhl, S., Felsenreich, D. M., Mairinger, M., Jedamzik, J., Richwien, P., Mozayani, B., Semmler, G., Balcar, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67415-w · Cited by 26
Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis—a pilot study
Schulz, M., Wilde, A. B., Demir, M., Müller, T., Tacke, F., & Wree, A. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-21-657 · Cited by 26
Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink
Fernandez, C. J., Alkhalifah, M. K., Afzar, H., & Pappachan, J. M. (2024) · Pathogens · doi:10.3390/pathogens13010068 · Cited by 29
Liver Fat Content and Body Fat Distribution in Youths with Excess Adiposity
Ramírez‐Vélez, R., Izquierdo, M., Correa‐Bautista, J. E., Correa‐Rodríguez, M., Schmidt‐RioValle, J., González‐Jiménez, E., & González-Jiménez, K. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120528 · Cited by 26
Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV
Aepfelbacher, J., Balmaceda, J. B., Purdy, J., Mattingly, A. S., Zambell, K. L., Hawkins, K., Chairez, C. L., Curl, K.-A., Dee, N., & Hadigan, C. M. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz096 · Cited by 28
Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults
Li, S., Li, F., Ding, J., Zhou, W., Yuan, T., & Mao, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03007-8 · Cited by 25
Intersecting Pathways: Nonalcoholic Fatty Liver Disease and Psoriasis Duet—A Comprehensive Review
Costache, D. O., Blejan, H., Cojocaru, D. L., Ioniță, G., Poenaru, M., Constantin, M. M., Costache, A. C., Căruntu, C., Balaban, D. V., & Costache, R. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052660 · Cited by 25
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
Feng, Z., Zhao, F., Wang, Z., Tang, X., Xie, Y., & Li, Q. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03192-0 · Cited by 25
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25
Self-citation
Diagnostic performance of sixteen biomarkers for MASLD: A study in a Mexican cohort
Priego-Parra, B. A., Reyes-Diaz, S. A., Alvarez, H. R. O., Bernal-Reyes, R., Icaza-Chávez, M. E., Vázquez, S., Amieva‐Balmori, M., Vivanco-Cid, H., Velasco, J. A. V.-R., Gracia‐Sancho, J., et al. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102400 · Cited by 25
Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease
Piccinni, R., Rodrigues, S. G., Montani, M., Murgia, G., Delgado, M., Casu, S., Stirnimann, G., Semmo, N., Gottardi, A. D., Dufour, J., et al. (2019) · Liver International · doi:10.1111/liv.14325 · Cited by 25
Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease
Mendoza, Y. P., Cocciolillo, S., Murgia, G., Chen, T., Margini, C., Sebastiani, G., & Berzigotti, A. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.018 · Cited by 25
Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard
Ajmera, V. H., Cachay, E. R., Ramers, C. B., Bassirian, S., Singh, S., Bettencourt, R., Richards, L., Hamilton, G., Middleton, M. S., Fowler, K. J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa429 · Cited by 25
Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference
Kozłowska‐Petriczko, K., Wunsch, E., Petriczko, J., Syn, W., & Milkiewicz, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071507 · Cited by 25
Transient Elastography in Pediatric Liver Disease
Banc‐Husu, A. M., & Bass, L. M. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003168 · Cited by 25
Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease
Chen, X., Goh, G. B., Huang, J., Wu, Y., Wang, M.-F., Kumar, R., Lin, S., & Zhu, Y. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00311 · Cited by 25
Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community‐Based Sample of Mexican‐Origin Adults
Garcia, D., Morrill, K., Lopez-Pentecost, M., Villavicencio, E., Vogel, R. M., Bell, M., Klimentidis, Y., Marrero, D., & Thomson, C. (2022) · Hepatology Communications · doi:10.1002/hep4.1896 · Cited by 22
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03579-1 · Cited by 25
How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography—A Review of the Literature and Proposed Multistep Approach
Țâru, M.-G., Neamți, L., Țâru, V., Procopciuc, L. M., Procopeț, B., & Lupșor‐Platon, M. (2023) · Diagnostics · doi:10.3390/diagnostics13040788 · Cited by 25
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging
Lascio, N. D., Avigo, C., Salvati, A., Martini, N., Ragucci, M., Monti, S., Prinster, A., Chiappino, D., Mancini, M., D'Elia, D., et al. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.03.011 · Cited by 25
Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China
Liu, D., Shen, Y., Zhang, R., Xun, J., Wang, J., Liu, L., Steinhart, C. R., Chen, J., & Lu, H. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15320 · Cited by 25
Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease
Margini, C., Murgia, G., Stirnimann, G., Gottardi, A. D., Semmo, N., Casu, S., Bosch, J., Dufour, J., & Berzigotti, A. (2018) · Hepatology Communications · doi:10.1002/hep4.1201 · Cited by 24
Effect of silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B
Lv, D., Wang, Y., Wang, M.-L., Chen, E., Tao, Y.-C., Zhang, D., & Tang, H. (2021) · Scientific Reports · doi:10.1038/s41598-020-80709-z · Cited by 24
Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease
Ng, Y. Z., Lai, L. L., Wong, S., Mohamad, S. Y., Chuah, K. H., & Chan, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250300 · Cited by 24
Self-citation
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study
Han, W. M., Apornpong, T., Lwin, H. M. S., Thammapiwan, S., Boonrungsirisap, J., Gatechompol, S., Ubolyam, S., Tangkijvanich, P., Kerr, S. J., & Avihingsanon, A. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad433 · Cited by 24
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research
Mancini, M., Summers, P. E., Faita, F., Brunetto, M. R., Callea, F., Nicola, A. D., Lascio, N. D., Farinati, F., Gastaldelli, A., Gridelli, B. G., et al. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i2.231 · Cited by 24
Evaluation of the Hepatorenal B-Mode Ratio and the “Controlled Attenuation Parameter” for the Detection and Grading of Steatosis
Moret, A., Boursier, J., Debry, P. H., Riou, J., Crouan, A., Dubois, M., Provost, S. M., Aubé, C., & Paisant, A. (2020) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-1233-2290 · Cited by 24
Comparing Three Ultrasound-Based Techniques for Diagnosing and Grading Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
Wang, P., Song, D., Han, J., Zhang, J., Chen, H., Gao, R., Shen, H., & Li, J. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.002 · Cited by 23
Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community
Hansen, C. D., Hansen, J. K., Israelsen, M. E., Andersen, P., Pikkupeura, L. M., Lindvig, K. P., Stinson, S. E., Schnefeld, H. L., Tellerup, J., Fogt, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.020 · Cited by 23

Authors: Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., Ferraioli, G., Chan, W.-K., Wong, V. W.-S., Myers, R. P., Chayama, K., Friedrich-Rust, M., Beaugrand, M., Shen, F., Hiriart, J.-B., Sarin, S. K., Badea, R., Jung, K. S., Marcellin, P., Filice, C., Mahadeva, S., Wong, G. L.-H., Crotty, P., Masaki, K., Bojunga, J., Bedossa, P., Keim, V., & Wiegand, J.
Affiliations: University Hospital Leipzig (DE)
IFB Adiposity Diseases (DE)
Echosens (France) (FR)
Shanghai Jiao Tong University (CN)
Institute of Liver and Biliary Sciences (IN)
Yonsei University (KR)
Inserm (FR)
University of Pavia (IT)
University of Malaya (MY)
Chinese University of Hong Kong (HK)
University of Calgary (CA)
Hiroshima University Hospital (JP)
Hôpital Jean-Verdier (FR)
Centre Hospitalier Universitaire de Bordeaux (FR)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
University Hospital Frankfurt (DE)
Corresponding author: Wiegand, Johannes
ORCID: Karlas, Thomas
Petroff, David
Sasso, Magali
Fan, Jian-Gao
Kumar, Manoj
Han, Kwang-Hyub
Cardoso, Ana C.
Ferraioli, Giovanna
Chan, Wah-Kheong
Wong, Vincent Wai-Sun
Chayama, Kazuaki
Shen, Feng
Hiriart, Jean-Baptiste
Sarin, Shiv K.
Badea, Radu
Marcellin, Patrick
Mahadeva, Sanjiv
Wong, Grace Lai-Hung
Crotty, Pam
Bojunga, Joerg
Wiegand, Johannes
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1022-1030
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2016.12.022
OpenAlex: W2564467149
Cited by: 1,275
References: 65
Citations by year: 2026: 164 · 2025: 185 · 2024: 180 · 2023: 139 · 2022: 161 · 2021: 150 · 2020: 117 · 2019: 77 · 2018: 67 · 2017: 31
FWCI: 7.94
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Ultrasound Imaging and Elastography
Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Ultrasound in Clinical Applications
Keywords: controlled attenuation parameter, hepatic steatosis, vibration-controlled transient elastography, FibroScan, chronic liver disease, diabetes mellitus, body mass index, liver ultrasound, receiver operating characteristic
MeSH terms: Adult, Fatty Liver, Female, Humans, Male, Middle Aged, ROC Curve, Ultrasonography, Meta-Analysis as Topic, Body Mass Index, Hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks